{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:27:34Z","timestamp":1794475654446,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG391151-3 and CMRPG3D0431-2"],"award-info":[{"award-number":["CMRPG391151-3 and CMRPG3D0431-2"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, oligo- or anovulation, and\/or polycystic ovary. It frequently presents with dyslipidemia and insulin resistance. Recent studies have shown that the white adipose tissue-derived asprosin is elevated in humans with insulin resistance. Because many PCOS patients have a propensity to develop dyslipidemia and\/or insulin resistance, asprosin metabolism could be dysregulated in PCOS patients. Accordingly, we investigated serum levels of asprosin, irisin, GIP, androgens, LH, glucose, insulin, and lipids as well as HOMA-IR, QUICKI and ISI <jats:sub>Matsuda<\/jats:sub> in a cohort of 444 PCOS patients and 156 controls. Patients were stratified based on metabolic syndrome risk factors (ATPIII [+] and [\u2212] groups), or BMI (overweight and lean groups). The irisin level was significantly correlated with body weight, SBP, DBP, Ferriman\u2013Gallwey score, and levels of TSH, triglycerides, glucose and insulin in the overall population, and was elevated in ATPIII(+) and overweight PCOS patients compared to corresponding controls. By contrast, asprosin levels in PCOS, ATPIII(+), or overweight patients were similar to those of corresponding controls. This finding indicated that the regulation of irisin, but not asprosin, metabolism is abnormal in PCOS patients, and this metabolic characteristic is distinctly different from that of diabetes patients.<\/jats:p>","DOI":"10.1038\/s41598-019-42061-9","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T10:03:39Z","timestamp":1556013819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients"],"prefix":"10.1038","volume":"9","author":[{"given":"Chia Lin","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya Chiung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu Hsuan","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung Kuei","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"42061_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrendo.2010.217","volume":"7","author":"MO Goodarzi","year":"2011","unstructured":"Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G. & Azziz, R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 7, 219\u2013231 (2011).","journal-title":"Nat Rev Endocrinol"},{"key":"42061_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dep399","volume":"25","author":"WA March","year":"2010","unstructured":"March, W. A. et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25, 544\u2013551 (2010).","journal-title":"Hum Reprod"},{"key":"42061_CR3","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jcem.84.11.6148","volume":"84","author":"E Diamanti-Kandarakis","year":"1999","unstructured":"Diamanti-Kandarakis, E. et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84, 4006\u20134011 (1999).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","volume":"97","author":"BC Fauser","year":"2012","unstructured":"Fauser, B. C. et al. Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97, 28\u201338 e25 (2012).","journal-title":"Fertil Steril"},{"key":"42061_CR5","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.2337\/diacare.26.12.3331","volume":"26","author":"S Genuth","year":"2003","unstructured":"Genuth, S. et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26, 3160\u20133167 (2003).","journal-title":"Diabetes Care"},{"key":"42061_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"Diamanti-Kandarakis, E. & Dunaif, A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33, 981\u20131030 (2012).","journal-title":"Endocr Rev"},{"key":"42061_CR7","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro, R. S. et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98, 4565\u20134592 (2013).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/humupd\/dmi013","volume":"11","author":"DH Abbott","year":"2005","unstructured":"Abbott, D. H., Barnett, D. K., Bruns, C. M. & Dumesic, D. A. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 11, 357\u2013374 (2005).","journal-title":"Hum Reprod Update"},{"key":"42061_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"Azziz, R. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91, 456\u2013488 (2009).","journal-title":"Fertil Steril"},{"key":"42061_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1210\/mend.13.6.0311","volume":"13","author":"VL Nelson","year":"1999","unstructured":"Nelson, V. L., Legro, R. S., Strauss, J. F. 3rd & McAllister, J. M. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 13, 946\u2013957 (1999).","journal-title":"Mol Endocrinol"},{"key":"42061_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1210\/edrv.20.4.0374","volume":"20","author":"L Poretsky","year":"1999","unstructured":"Poretsky, L., Cataldo, N. A., Rosenwaks, Z. & Giudice, L. C. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20, 535\u2013582 (1999).","journal-title":"Endocr Rev"},{"key":"42061_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/JCI113864","volume":"83","author":"A Dunaif","year":"1989","unstructured":"Dunaif, A. & Graf, M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J Clin Invest 83, 23\u201329 (1989).","journal-title":"J Clin Invest"},{"key":"42061_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1210\/jc.2003-030932","volume":"89","author":"JS Laven","year":"2004","unstructured":"Laven, J. S. et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89, 318\u2013323 (2004).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR14","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1210\/jc.2003-030727","volume":"88","author":"P Pigny","year":"2003","unstructured":"Pigny, P. et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88, 5957\u20135962 (2003).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/humrep\/det015","volume":"28","author":"R Homburg","year":"2013","unstructured":"Homburg, R. et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 28, 1077\u20131083 (2013).","journal-title":"Hum Reprod"},{"key":"42061_CR16","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1515\/jpem-2012-0013","volume":"25","author":"M Pawelczak","year":"2012","unstructured":"Pawelczak, M., Kenigsberg, L., Milla, S., Liu, Y. H. & Shah, B. Elevated serum anti-Mullerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. J Pediatr Endocrinol Metab 25, 983\u2013989 (2012).","journal-title":"J Pediatr Endocrinol Metab"},{"key":"42061_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/oby.21029","volume":"23","author":"B Palacios-Gonzalez","year":"2015","unstructured":"Palacios-Gonzalez, B. et al. Irisin levels before and after physical activity among school-age children with different BMI: a direct relation with leptin. Obesity (Silver Spring) 23, 729\u2013732 (2015).","journal-title":"Obesity (Silver Spring)"},{"key":"42061_CR18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.12891\/ceog16522014","volume":"41","author":"B Yildirim","year":"2014","unstructured":"Yildirim, B., Celik, O. & Aydin, S. Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Clin Exp Obstet Gynecol 41, 310\u2013312 (2014).","journal-title":"Clin Exp Obstet Gynecol"},{"key":"42061_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrendo.2016.66","volume":"12","author":"C Greenhill","year":"2016","unstructured":"Greenhill, C. Liver: Asprosin - new hormone involved in hepatic glucose release. Nat Rev Endocrinol 12, 312 (2016).","journal-title":"Nat Rev Endocrinol"},{"key":"42061_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"Romere, C. et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell 165, 566\u2013579 (2016).","journal-title":"Cell"},{"key":"42061_CR21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/nm.4432","volume":"23","author":"C Duerrschmid","year":"2017","unstructured":"Duerrschmid, C. et al. Asprosin is a centrally acting orexigenic hormone. Nat Med 23, 1444\u20131453 (2017).","journal-title":"Nat Med"},{"key":"42061_CR22","unstructured":"Zhang, L., Chen, C., Zhou, N., Fu, Y. & Cheng, X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta (2017)."},{"key":"42061_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","volume":"109","author":"SM Grundy","year":"2004","unstructured":"Grundy, S. M., Brewer, H. B. Jr., Cleeman, J. I., Smith, S. C. Jr. & Lenfant, C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition. Circulation 109, 433\u2013438 (2004).","journal-title":"Circulation"},{"key":"42061_CR24","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.cell.2018.10.025","volume":"175","author":"H Kim","year":"2018","unstructured":"Kim, H. et al. Irisin Mediates Effects on Bone and Fat via alphaV Integrin Receptors. Cell 175, 1756\u20131768 e1717 (2018).","journal-title":"Cell"},{"key":"42061_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1055\/s-0042-108730","volume":"48","author":"XL Du","year":"2016","unstructured":"Du, X. L., Jiang, W. X. & Lv, Z. T. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Horm Metab Res 48, 644\u2013652 (2016).","journal-title":"Horm Metab Res"},{"key":"42061_CR26","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1210\/jc.2013-2373","volume":"98","author":"K Hee Park","year":"2013","unstructured":"Hee Park, K. et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 98, 4899\u20134907 (2013).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR27","doi-asserted-by":"publisher","first-page":"e3742","DOI":"10.1097\/MD.0000000000003742","volume":"95","author":"JH Huh","year":"2016","unstructured":"Huh, J. H., Ahn, S. V., Choi, J. H., Koh, S. B. & Chung, C. H. High Serum Irisin Level as an Independent Predictor of Diabetes Mellitus: A Longitudinal Population-Based Study. Medicine (Baltimore) 95, e3742 (2016).","journal-title":"Medicine (Baltimore)"},{"key":"42061_CR28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2337\/db13-1106","volume":"63","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 63, 514\u2013525 (2014).","journal-title":"Diabetes"},{"key":"42061_CR29","doi-asserted-by":"publisher","first-page":"E2154","DOI":"10.1210\/jc.2014-1437","volume":"99","author":"JY Huh","year":"2014","unstructured":"Huh, J. Y. et al. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab 99, E2154\u20132161 (2014).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR30","doi-asserted-by":"publisher","first-page":"e110273","DOI":"10.1371\/journal.pone.0110273","volume":"9","author":"H Song","year":"2014","unstructured":"Song, H. et al. Irisin promotes human umbilical vein endothelial cell proliferation through the ERK signaling pathway and partly suppresses high glucose-induced apoptosis. PLoS One 9, e110273 (2014).","journal-title":"PLoS One"},{"key":"42061_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ijo.2015.199","volume":"40","author":"C Xin","year":"2016","unstructured":"Xin, C. et al. Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obes (Lond) 40, 443\u2013451 (2016).","journal-title":"Int J Obes (Lond)"},{"key":"42061_CR32","doi-asserted-by":"publisher","first-page":"H1501","DOI":"10.1152\/ajpheart.00443.2015","volume":"309","author":"F Han","year":"2015","unstructured":"Han, F., Zhang, S., Hou, N., Wang, D. & Sun, X. Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway. Am J Physiol Heart Circ Physiol 309, H1501\u20131508 (2015).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"42061_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature10777","volume":"481","author":"P Bostrom","year":"2012","unstructured":"Bostrom, P. et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463\u2013468 (2012).","journal-title":"Nature"},{"key":"42061_CR34","doi-asserted-by":"publisher","first-page":"E769","DOI":"10.1210\/jc.2012-2749","volume":"98","author":"JM Moreno-Navarrete","year":"2013","unstructured":"Moreno-Navarrete, J. M. et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98, E769\u2013778 (2013).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrendo.2012.49","volume":"8","author":"BK Pedersen","year":"2012","unstructured":"Pedersen, B. K. & Febbraio, M. A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8, 457\u2013465 (2012).","journal-title":"Nat Rev Endocrinol"},{"key":"42061_CR36","doi-asserted-by":"publisher","first-page":"e0120354","DOI":"10.1371\/journal.pone.0120354","volume":"10","author":"E Miyamoto-Mikami","year":"2015","unstructured":"Miyamoto-Mikami, E. et al. Endurance training-induced increase in circulating irisin levels is associated with reduction of abdominal visceral fat in middle-aged and older adults. PLoS One 10, e0120354 (2015).","journal-title":"PLoS One"},{"key":"42061_CR37","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.metabol.2015.05.010","volume":"64","author":"Y Tsuchiya","year":"2015","unstructured":"Tsuchiya, Y., Ando, D., Takamatsu, K. & Goto, K. Resistance exercise induces a greater irisin response than endurance exercise. Metabolism 64, 1042\u20131050 (2015).","journal-title":"Metabolism"},{"key":"42061_CR38","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/17461391.2017.1296025","volume":"17","author":"IL Bonfante","year":"2017","unstructured":"Bonfante, I. L. et al. Combined training, FNDC5\/irisin levels and metabolic markers in obese men: A randomised controlled trial. Eur J Sport Sci 17, 629\u2013637 (2017).","journal-title":"Eur J Sport Sci"},{"key":"42061_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.metabol.2016.12.003","volume":"68","author":"DJ Li","year":"2017","unstructured":"Li, D. J., Li, Y. H., Yuan, H. B., Qu, L. F. & Wang, P. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1\/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism 68, 31\u201342 (2017).","journal-title":"Metabolism"},{"key":"42061_CR40","doi-asserted-by":"publisher","first-page":"e0154319","DOI":"10.1371\/journal.pone.0154319","volume":"11","author":"S Oelmann","year":"2016","unstructured":"Oelmann, S., Nauck, M., Volzke, H., Bahls, M. & Friedrich, N. Circulating Irisin Concentrations Are Associated with a Favourable Lipid Profile in the General Population. PLoS One 11, e0154319 (2016).","journal-title":"PLoS One"},{"key":"42061_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yjmcc.2015.07.015","volume":"87","author":"D Zhu","year":"2015","unstructured":"Zhu, D. et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative\/nitrative stresses. J Mol Cell Cardiol 87, 138\u2013147 (2015).","journal-title":"J Mol Cell Cardiol"},{"key":"42061_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jdiacomp.2013.03.002","volume":"27","author":"JJ Liu","year":"2013","unstructured":"Liu, J. J. et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 27, 365\u2013369 (2013).","journal-title":"J Diabetes Complications"},{"key":"42061_CR43","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3109\/09513590.2014.920006","volume":"30","author":"M Kuzmicki","year":"2014","unstructured":"Kuzmicki, M. et al. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol 30, 636\u2013639 (2014).","journal-title":"Gynecol Endocrinol"},{"key":"42061_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/1753-0407.12256","volume":"8","author":"C Zhang","year":"2016","unstructured":"Zhang, C. et al. Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis. J Diabetes 8, 56\u201362 (2016).","journal-title":"J Diabetes"},{"key":"42061_CR45","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.clinbiochem.2015.07.098","volume":"48","author":"ID Duran","year":"2015","unstructured":"Duran, I. D. et al. Irisin levels in the progression of diabetes in sedentary women. Clin Biochem 48, 1268\u20131272 (2015).","journal-title":"Clin Biochem"},{"key":"42061_CR46","doi-asserted-by":"crossref","unstructured":"Liu, J. J. et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications (2013).","DOI":"10.1016\/j.jdiacomp.2013.03.002"},{"key":"42061_CR47","doi-asserted-by":"crossref","unstructured":"Choi, Y. K. et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract (2013).","DOI":"10.1016\/j.diabres.2013.01.007"},{"key":"42061_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrendo.2013.230","volume":"10","author":"PA Bostrom","year":"2014","unstructured":"Bostrom, P. A. & Fernandez-Real, J. M. Metabolism: Irisin, the metabolic syndrome and follistatin in humans. Nat Rev Endocrinol 10, 11\u201312 (2014).","journal-title":"Nat Rev Endocrinol"},{"key":"42061_CR49","unstructured":"Kuzmicki, M. et al. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol, 1\u20134 (2014)."},{"key":"42061_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.diabres.2013.12.025","volume":"104","author":"MA Yuksel","year":"2014","unstructured":"Yuksel, M. A. et al. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract 104, 171\u2013175 (2014).","journal-title":"Diabetes Res Clin Pract"},{"key":"42061_CR51","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1080\/01443615.2017.1399260","volume":"38","author":"A Ozel","year":"2018","unstructured":"Ozel, A. et al. Maternal serum irisin levels in early and late-onset pre-eclamptic and healthy pregnancies. J Obstet Gynaecol 38, 642\u2013646 (2018).","journal-title":"J Obstet Gynaecol"},{"key":"42061_CR52","doi-asserted-by":"publisher","first-page":"E2539","DOI":"10.1210\/jc.2014-1180","volume":"99","author":"CL Chang","year":"2014","unstructured":"Chang, C. L. et al. Circulating irisin and glucose-dependent insulinotropic peptide are associated with the development of polycystic ovary syndrome. J Clin Endocrinol Metab 99, E2539\u20132548 (2014).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR53","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3109\/01443615.2016.1174200","volume":"36","author":"R Abali","year":"2016","unstructured":"Abali, R. et al. Implications of circulating irisin and Fabp4 levels in patients with polycystic ovary syndrome. J Obstet Gynaecol 36, 897\u2013901 (2016).","journal-title":"J Obstet Gynaecol"},{"key":"42061_CR54","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1507\/endocrj.EJ16-0249","volume":"63","author":"A Adamska","year":"2016","unstructured":"Adamska, A. et al. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Endocr J 63, 1107\u20131112 (2016).","journal-title":"Endocr J"},{"key":"42061_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40618-015-0403-7","volume":"39","author":"H Li","year":"2016","unstructured":"Li, H. et al. Free androgen index and Irisin in polycystic ovary syndrome. J Endocrinol Invest 39, 549\u2013556 (2016).","journal-title":"J Endocrinol Invest"},{"key":"42061_CR56","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1210\/jc.2014-2544","volume":"100","author":"M Li","year":"2015","unstructured":"Li, M. et al. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab 100, 1485\u20131493 (2015).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR57","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3109\/09513590.2015.1065482","volume":"31","author":"K Pukajlo","year":"2015","unstructured":"Pukajlo, K. et al. Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. Gynecol Endocrinol 31, 907\u2013911 (2015).","journal-title":"Gynecol Endocrinol"},{"key":"42061_CR58","first-page":"4462","volume":"19","author":"MS Bostanci","year":"2015","unstructured":"Bostanci, M. S. et al. Serum irisin levels in patients with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 19, 4462\u20134468 (2015).","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"42061_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.rbmo.2017.10.114","volume":"36","author":"X Cai","year":"2018","unstructured":"Cai, X. et al. Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis. Reprod Biomed Online 36, 172\u2013180 (2018).","journal-title":"Reprod Biomed Online"},{"key":"42061_CR60","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-17-0572","volume":"177","author":"AB Cooke","year":"2017","unstructured":"Cooke, A. B., Gomez, Y. H. & Daskalopoulou, S. S. 5 years later: irisin detection still an issue. Eur J Endocrinol 177, C1\u2013C4 (2017).","journal-title":"Eur J Endocrinol"},{"key":"42061_CR61","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2004-1045","volume":"90","author":"T Apridonidze","year":"2005","unstructured":"Apridonidze, T., Essah, P. A., Iuorno, M. J. & Nestler, J. E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90, 1929\u20131935 (2005).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR62","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1210\/jc.2007-0425","volume":"93","author":"LJ Shaw","year":"2008","unstructured":"Shaw, L. J. et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health\u2013National Heart, Lung, and Blood Institute sponsored Women\u2019s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93, 1276\u20131284 (2008).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR63","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1210\/jc.2004-1843","volume":"90","author":"RS Legro","year":"2005","unstructured":"Legro, R. S., Gnatuk, C. L., Kunselman, A. R. & Dunaif, A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90, 3236\u20133242 (2005).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR64","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1210\/jc.2013-4127","volume":"99","author":"MF Garces","year":"2014","unstructured":"Garces, M. F. et al. Irisin levels during pregnancy and changes associated with the development of preeclampsia. J Clin Endocrinol Metab 99, 2113\u20132119 (2014).","journal-title":"J Clin Endocrinol Metab"},{"key":"42061_CR65","doi-asserted-by":"crossref","unstructured":"Sesti, G. et al. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol (2014).","DOI":"10.1007\/s00592-014-0576-0"},{"key":"42061_CR66","doi-asserted-by":"crossref","unstructured":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19, 41\u201347 (2004).","DOI":"10.1093\/humrep\/deh098"},{"key":"42061_CR67","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian, S. et al. Quantification of lean bodyweight. Clin Pharmacokinet 44, 1051\u20131065 (2005).","journal-title":"Clin Pharmacokinet"},{"key":"42061_CR68","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/oby.2011.38","volume":"19","author":"RN Bergman","year":"2011","unstructured":"Bergman, R. N. et al. A better index of body adiposity. Obesity (Silver Spring) 19, 1083\u20131089 (2011).","journal-title":"Obesity (Silver Spring)"},{"key":"42061_CR69","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s001250051561","volume":"43","author":"M Albareda","year":"2000","unstructured":"Albareda, M., Rodriguez-Espinosa, J., Murugo, M., de Leiva, A. & Corcoy, R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43, 1507\u20131511 (2000).","journal-title":"Diabetologia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42061-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:59:17Z","timestamp":1671267557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42061-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42061"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42061-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"30 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6447"}}